Biodiscovery
Teesside University embarked on a project to discover new biomarkers and develop personalised therapies for colorectal cancer (CRC). The goal was to improve early detection and create targeted treatments to enhance patient outcomes.
Colorectal cancer is a leading cause of cancer-related deaths worldwide, and current treatment methods are often not tailored to individual patients. The challenge was to identify biomarkers that could detect CRC early and develop personalised therapies to improve treatment effectiveness.
The research team used advanced techniques in biochemistry and genetics to identify new biomarkers associated with CRC. They applied quantitative live imaging and super-resolution microscopy to study cancer cells and their genetic signatures. This research aimed to uncover new indicators of the disease and develop therapies that target these specific biomarkers.
The project led to significant advancements in CRC diagnosis and treatment. The identification of new biomarkers promises earlier detection and more effective treatments tailored to individual patients. The research’s outcomes have the potential to improve survival rates and quality of life for CRC patients, marking a significant step forward in cancer research and treatment.
